Format

Send to

Choose Destination
Curr Opin Pharmacol. 2014 Apr;15:16-21. doi: 10.1016/j.coph.2013.11.004. Epub 2013 Nov 27.

Cardiac safety assays.

Author information

1
Institute of Pharmacology, Faculty of Medicine, University Duisburg-Essen, Essen, Germany.
2
AstraZeneca Research & Development, Bioscience, Mölndal, Sweden.
3
Institute of Pharmacology, Faculty of Medicine, University Duisburg-Essen, Essen, Germany. Electronic address: Dobromir.Dobrev@uk-essen.de.

Abstract

Cardiac safety, including the risk of drug-induced 'torsades de pointes' (TdP) arrhythmia, is a major concern in the development, approval and prescription of new drugs. Assessment of surrogate markers of TdP-risk, such as QT-interval prolongation or inhibition of the rapid delayed-rectifier K(+)-current (IKr) encoded by the human ether-a-go-go-related gene (hERG), is therefore required before drug approval. Here, we review some methodologies employed to assess proarrhythmia liability of drugs, discuss the challenges involved in this process, and highlight promising novel cardiac-safety assays.

PMID:
24721649
DOI:
10.1016/j.coph.2013.11.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center